EGFR and lung cancer: NSCLC constitutes the major part (approximately 75%) of lung cancer and the overexpression of EGFR in this cancer has been associated with drug resistance and a decreased survival rate (Ogawa et al., 1993; Veale et al., 1993; Fontanini et al., 1998; Scagliotti et al., 2004).